Recombinant botulinum toxin (biosynthetic Botox)

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) replace the traditional Clostridium botulinum batch fermentation — a high-containment, low-yield process tied to the 900 kDa toxin complex — with biosynthetic production (recombinant serotype expression in microbial or cell-free systems) or downstream engineering that strips the complexing proteins to deliver a “naked” 150 kDa neurotoxin. The global botulinum toxin market exceeded $7 billion in 2026, with AbbVie’s Botox franchise commanding approximately 60% of US neuromodulator share. Three differentiated product profiles launched or won approval in 2026: AbbVie/Allergan’s Boey® (trenibotulinumtoxinE) — the first recombinant botulinum neurotoxin serotype E approved for aesthetic use, with onset as early as 8 hours and effects lasting 2-3 weeks across 2,100+ Phase 3 patients; Galderma’s Relfydess™ (relabotulinumtoxinA) — the first ready-to-use liquid neuromodulator manufactured with PEARL™ Technology, complex-free BoNT-A1 with onset as early as Day 1 and 6-month sustained effect in roughly 75% of patients across 1,900+ READY trial participants; and Eirion Therapeutics’ AI-09 — a ready-to-use liquid injectable recombinant BoNT-A that achieved a median 26-week (6-month) duration at the highest dose in a 96-subject Phase 1-2 trial. Merz’s Xeomin (incobotulinumtoxinA, approved in 79 countries) pioneered the complexing-protein-free “naked toxin” profile. The serotype E Boey approval (Health Canada June 2026, EU July 2026, FDA Complete Response Letter April 2026 citing manufacturing only) marks the first new botulinum neurotoxin serotype approved for aesthetic use since the original BoNT-A products.

The key directions of recombinant botulinum toxin are:

1. Recombinant serotype-E neurotoxin (TrenibotulinumtoxinE / Boey): AbbVie/Allergan’s first-in-class recombinant BoNT/E targeting SNAP-25, with onset as early as 8 hours and 2-3 week duration, approved in Canada (June 23, 2026) and across the 30 EEA countries (July 17, 2026) following a positive CHMP opinion (May 21, 2026); US BLA under Complete Response Letter (April 23, 2026) for manufacturing only, no additional clinical studies requested.
2. Ready-to-use liquid neuromodulators (PEARL Technology): Galderma’s Relfydess™ (relabotulinumtoxinA, formerly QM1114) — first ready-to-use liquid neuromodulator manufactured via Precipitation-free Extraction and Activity-preserving, Refined Liquid (PEARL™) Technology from a proprietary C. botulinum A1 strain, producing a complex-free BoNT-A1 molecule with day-1 onset and 6-month sustained effect; 33 markets approved, 20+ launched.
3. Complexing-protein-free naked toxin (Xeomin): Merz Therapeutics’ incobotulinumtoxinA — BoNT-A manufactured with proprietary purification technology that removes accessory complexing proteins during production, yielding the 150 kDa neurotoxin alone; approved in 79 countries, with Japan MHLW cervical-dystonia/blepharospasm approval (June 19, 2026) and EU pediatric spasticity submission (January 26, 2026) on Phase 3 ELLIE data.
4. Recombinant liquid injectable & topical neuromodulators (AI-09 / ET-01): Eirion Therapeutics’ AI-09 ready-to-use liquid injectable BoNT-A achieved 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial and entered Phase 2 (NCT07321834) in December 2025; ET-01 topical BoNT in Phase 2; backed by a $40M Haohai Biological Technology licensing deal and HTL Biotechnology (France) manufacturing.

Sectoral value chain#

[recombinant gene construct / proprietary C. botulinum A1 strain] ──> [upstream fermentation / cell culture]
                                                                                              │
                                                                              (150 kDa neurotoxin)
                                                                                              │
                                                                                              ▼
[ready-to-use liquid or lyophilized vial] <─── [fill-finish & QC] <─── [complexing-protein removal / PEARL formulation] <─── [chromatographic purification]

Value chain levels#

Cross-cutting technologies of the sector:

• PEARL™ Technology ready-to-use liquid formulation (PEARL Technology Ready-to-Use Liquid BoNT-A): Galderma’s Precipitation-free Extraction and Activity-preserving, Refined Liquid process delivers relabotulinumtoxinA as a stable complex-free liquid that requires no reconstitution, with a measured 0.27 ng BoNT-A1 per glabellar-line dose and 53 BoTest® activity units versus onabotulinumtoxinA’s 0.18 ng and 29 units.
• Complexing-protein-free naked toxin purification (Complexing-Protein-Free Naked Toxin Purification): Merz’s proprietary purification technology strips the 750 kDa neurotoxin-associated proteins during manufacturing, leaving only the 150 kDa active neurotoxin (incobotulinumtoxinA) — claimed to reduce immunogenicity risk over long treatment cycles.
• Ready-to-use recombinant liquid injectable (Ready-to-Use Recombinant Liquid Injectable Neuromodulator): Eirion’s AI-09 formulated as a ready-to-use liquid injectable BoNT-A, achieving a 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial and entering Phase 2 (NCT07321834) in December 2025.

The recombinant and next-generation BoNT stack rests on three engineering layers — serotype / molecule selection, complexing-protein downstream processing, and ready-to-use liquid formulation — each of which can differentiate a product on onset speed, duration, or immunogenicity profile.

1. Recombinant serotype-E expression (Recombinant BoNT Serotype E Expression):
   • AbbVie/Allergan’s Boey (trenibotulinumtoxinE) expresses BoNT serotype E (rather than the dominant serotype A of all prior aesthetic products), targeting SNAP-25 at a different cleavage site than BoNT/A and delivering a rapid-onset (8 hours), short-duration (2-3 weeks) profile aimed at neurotoxin-naive patients.
   • The Bonti-origin program is the first new botulinum neurotoxin serotype approved for aesthetic use since the original BoNT-A wave of the 1990s-2000s; supported by 2,100+ patients across the pivotal Phase 3 M21-500 and M21-508 trials plus an open-label safety study.
2. PEARL™ Technology complex-free liquid formulation (PEARL Technology Ready-to-Use Liquid BoNT-A):
   • Galderma’s Precipitation-free Extraction and Activity-preserving, Refined Liquid process produces relabotulinumtoxinA as a complex-free BoNT-A1 liquid from a proprietary C. botulinum A1 strain; the PubMed-characterized output delivers 0.27 ng BoNT-A1 per glabellar-line dose and 53 BoTest® units of specific enzyme activity, versus onabotulinumtoxinA’s 0.18 ng and 29 units — yielding earlier SNAP-25 cleavage and the day-1 onset seen in the 1,900+ patient READY trial.
   • Eliminates reconstitution entirely (the powder-to-liquid step required for Botox, Xeomin and Boey), enabling volumetric dosing and a longer shelf life as a stable liquid.
3. Complexing-protein-free naked toxin purification (Complexing-Protein-Free Naked Toxin Purification):
   • Merz’s proprietary purification technology removes the 750 kDa of neurotoxin-associated (complexing) proteins during manufacturing, leaving only the 150 kDa active incobotulinumtoxinA molecule — claimed to reduce immunogenicity risk over the long, repeated injection cycles typical of neurology (spasticity, cervical dystonia) and chronic migraine use.
   • Xeomin’s 79-country approval footprint (including Japan MHLW’s 4th and 5th indication authorizations for cervical dystonia and blepharospasm in June 2026) and the EU pediatric spasticity ELLIE Phase 3 submission (January 26, 2026) establish the complex-free architecture as a validated alternative to the full 900 kDa complex.